Argus Research analyst John Staszak downgrades McCormick & Co (NYSE:MKC) from Buy to Hold.
Kodiak Sciences Completes Enrollment In GLOW Phase 3 Clinical Trial Of Tarcocimab Tedromer (KSI-301) In Patients With Non-Proliferative Diabetic Retinopathy
odiak Sciences Inc. (NASDAQ:KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, today announced that it has